Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1 Randomized, Double-blind Dose-Escalating Study of Pfs230D1 in Combination With R21 in Matrix-M in Healthy African Adults

NCT06507605 is registered in ClinicalTrials.gov with Serum Institute of India Pvt. Ltd. as lead sponsor.

NCT NCT06507605
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06507605 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1 Randomized, Double-blind Dose-Escalating Study of Pfs230D1 in Combination With R21 in Matrix-M in Healthy African Adults
Lead sponsor
Serum Institute of India Pvt. Ltd.
Phase
Phase 1
Overall status
Completed
Start date
August 30, 2024
Completion date
January 24, 2026
Enrollment
240 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

prevention of malaria transmission and clinical malaria